Biopharmaceuticals

Development, manufacturing and analytics of monoclonal antibodies and other proteins

  • Excellent speakers, different perspectives
  • Compact knowledge transfer
  • All course days can be booked individually
  • Including learning assessment
  • Officially certified according to ISO 9001+21001

Online-Seminar

From 1.290,00 € plus VAT
Services & Process

Booking details

Online-Seminar

From 1.290,00 € plus VAT
Services & Process

The compact course with a content focus on the development, production and analytics of biotech drugs. Secure your place and qualify now! All three course days can be booked individually (single day = 1.290€ plus VAT) - for booking, please contact us!

Your speakers

Dr. Jörg Engelbergs

Dr. Jörg Engelbergs

Paul-Ehrlich-Institut, (PEI), Langen

Scientific-Regulatory Expert & Assessor Biomedicines;
Jörg Engelbergs holds a doctorate in biology with a focus on cell biology and biotechnology and has held…

Dr. Josef Gabelsberger

Dr. Josef Gabelsberger

Roche Diagnostics GmbH,
Penzberg

Josef Gabelsberger studied biology and biotechnology at the Technical University of Munich, where he gained his doctorate in microbiology. He then worked for a total of…

Dr. Monika Geiger

Dr. Monika Geiger

Lonza AG,
Basel, SWITZERLAND

Associate Director/Senior Group Leader
Dr Monika Geiger completed her studies in pharmacy at the Philipps University in Marburg in 1997. She received her licence to practise…

Dr. Sonja Matt

Dr. Sonja Matt

Paul-Ehrlich-Institut (PEI),
Langen

Sonja Matt has been working as a scientific assessor at the Paul-Ehrlich-Institut since 2016 and evaluates the pharmaceutical quality of monoclonal and polyclonal…

Dr. Anika Schröter

Dr. Anika Schröter

Dr. Anika Schroeter e.U.,
Vienna, AUSTRIA

Anika Schröter holds a PhD in toxicology and is a registered European Registered Toxicologist. Since 2014 she has been working as a consultant for clients in…

Dr. Matthias Germer

Dr. Matthias Germer

Biotest AG,
Dreieich GERMANY

Vice President Preclinical Research
Matthias Germer has been Head of Preclinical Research at Biotest AG since 1999 and is responsible for the non-clinical parts of study…

Dr. René Thürmer

Dr. René Thürmer

- requested -
Expert for Pharmaceutical Quality,
Bonn, GERMANY

Dr. René Thürmer studied chemistry at the University of Tübingen, where he obtained his doctorate in 1999. He has been working in a public…

What to Expect

    Development & manufacturing on 2 December 2026:
  • Manufacturing process
  • Formulation
  • Process changes Regulatory requirements on 3 December 2026:
  • IMPD quality part
  • Non clinical aspects
  • Regulatory update: Biologics and biosimilars Biopharmaceutical analytics on 4 December 2026:
  • Method validation
  • Stability testing
  • Specifications

Who Should Attend

This course is aimed at specialists and managers in the pharmaceutical industry who are involved in the development, production and analysis of biotechnological drugs.

The focus on all three days will be on familiarising you with the regulatory framework with reference to guidelines.

In particular, employees in the departments of research & development, regulatory affairs, manufacturing, analytics, quality assurance and quality control will benefit from attending.

Objective of the Event

After day 1, you will be familiar with the specialties of galenic development process technologies and you will know what to look out for in process changes and comparability studies.

After day 2, you will be aware of critical quality parameters of biologics and biosimilars and know the challenges of the non-clinical program.

After day 3, you will have gained expertise in method validation, stability testing and specification writing.

Following Day 3, you will receive the access data for the optional online test for learning success control by e-mail.

Your Benefit

  • You know the current regulatory requirements for the (non-)clinical development of biologics and biosimilars
  • You know critical quality parameters of biopharmaceuticals
  • You know which data are required for the IMPD compilation and the quality documentation
  • You know specifics of proteins and what challenges to overcome in formulation development
  • You know which requirements exist for the manufacturing process of active ingredients and finished medicinal products - from clinical development to marketing authorisation - and you are familiar with the corresponding process technologies
  • You can implement comparability requirements in case of changes
  • You will be able to implement regulatory requirements for analytics, including method development/validation and setting and justifying specifications
  • You know the requirements for stability testing according to ICH and for method validation according to FDA

Programme

each day from 9:00 am till 5:00 pm

Day 1

Manufacturing process of the protein active ingredient
Dr Josef Gabelsberger
  • Production systems: Requirements
  • Practical challenges in development and manufacturing

Bio break

From active substance to protein formulation
Dr Monika Geiger
  • Peculiarities of proteins
  • Formulation development
  • Analytics for formulation development
  • Requirements for primary packaging materials

Lunch break

Active ingredient/finished drug product manufacturing process (from clinical development to MA): Requirements
Dr Jörg Engelbergs
  • Active substance characterisation and impurity profiles
  • Definition of specifications and acceptance criteria

Bio break

Comparability studies for manufacturing process changes
Dr Jörg Engelbergs
  • Demonstration of comparability during clinical development: requirements
  • Comparability exercise according to guideline ICH Q5E: Demonstration of comparability after approval
  • Ensuring regulatory compliance - change control: Variations & PACMPs

End of seminar day 1

Manufacturing process of the protein active ingredient

Dr Josef Gabelsberger

  • Production systems: Requirements
  • Practical challenges in development and manufacturing

Bio break

From active substance to protein formulation

Dr Monika Geiger

  • Peculiarities of proteins
  • Formulation development
  • Analytics for formulation development
  • Requirements for primary packaging materials

Lunch break

Active ingredient/finished drug product manufacturing process (from clinical development to MA): Requirements

Dr Jörg Engelbergs

  • Active substance characterisation and impurity profiles
  • Definition of specifications and acceptance criteria

Bio break

Comparability studies for manufacturing process changes

Dr Jörg Engelbergs

  • Demonstration of comparability during clinical development: requirements
  • Comparability exercise according to guideline ICH Q5E: Demonstration of comparability after approval
  • Ensuring regulatory compliance - change control: Variations & PACMPs

End of seminar day 1

Day 2

Requirements for the IMPD quality part
Dr Sonja Matt
  • Scope of the documentation
  • Status of process validation and analytical methods
  • Stability of IMP
  • Approaches for CTA (history and future)

Biologics: Non-clinical aspects I
Dr Anika Schröter
  • Standard requirements and deviation from the standard ("case-by-case")
  • Considerations for the determination of the starting dose in humans

Lunch break

Biologics: Non-clinical aspects II
Dr Anika Schröter

Update on regulatory landscape I
Dr Sonja Matt
  • Requirements for the evaluation of biosimilars
  • Definition of the similarity rank
  • Dealing with/and (non-)acceptance of differences

Bio break

Biosimilars: Non-clinical aspects
Dr Anika Schröter
  • Regulatory requirements

Update on regulatory landscape II
Dr Sonja Matt
  • Process validation: Innovations
  • Product and process development: QbD
  • Immunogenicity: Assessment
  • ICH Q12 & post approval change management protocol (PACMP)

Recap, Q&As and end of seminar day 2

Requirements for the IMPD quality part

Dr Sonja Matt

  • Scope of the documentation
  • Status of process validation and analytical methods
  • Stability of IMP
  • Approaches for CTA (history and future)

Biologics: Non-clinical aspects I

Dr Anika Schröter

  • Standard requirements and deviation from the standard ("case-by-case")
  • Considerations for the determination of the starting dose in humans

Lunch break

Biologics: Non-clinical aspects II

Update on regulatory landscape I

Dr Sonja Matt

  • Requirements for the evaluation of biosimilars
  • Definition of the similarity rank
  • Dealing with/and (non-)acceptance of differences

Bio break

Biosimilars: Non-clinical aspects

Dr Anika Schröter

  • Regulatory requirements

Update on regulatory landscape II

Dr Sonja Matt

  • Process validation: Innovations
  • Product and process development: QbD
  • Immunogenicity: Assessment
  • ICH Q12 & post approval change management protocol (PACMP)

Recap, Q&As and end of seminar day 2

Day 3

Analytics for clinical IMPs
Dr Matthias Germer

Bio break

Development and validation of analytical methods: Requirements for the registration dossier
Dr René Thürmer
  • Validation of protein analytical methods
  • Qualification of impurities in active ingredients and finished products
  • Typical dossier deficiencies

Lunch break

Stability studies
Dr Matthias Germer
  • Target setting; requirements for formal stability testing according to ICH

Update on ICH Q14: Development of analytical methods
Dr René Thürmer

Bio break

Setting, justifying and changing specifications
Dr René Thürmer
  • Implementation of the ICH Q6B Guideline
  • Critical quality attributes, common errors and defects - case studies
  • Contamination specifications of drug substance and drug product
  • Regulations/responsibilities in the context of clinical studies/registration

Recap and Q&As day 3

End of seminar

Analytics for clinical IMPs

Bio break

Development and validation of analytical methods: Requirements for the registration dossier

Dr René Thürmer

  • Validation of protein analytical methods
  • Qualification of impurities in active ingredients and finished products
  • Typical dossier deficiencies

Lunch break

Stability studies

Dr Matthias Germer

  • Target setting; requirements for formal stability testing according to ICH

Update on ICH Q14: Development of analytical methods

Bio break

Setting, justifying and changing specifications

Dr René Thürmer

  • Implementation of the ICH Q6B Guideline
  • Critical quality attributes, common errors and defects - case studies
  • Contamination specifications of drug substance and drug product
  • Regulations/responsibilities in the context of clinical studies/registration

Recap and Q&As day 3

End of seminar

Downloads

Request the documents using our form.

Abbreviation list Biotech

Weitere Informationen


Booking of individual course days

All three course days can be booked individually (a single day of your choice = €1,290 plus VAT).

For booking, please contact us!


Modular qualification program for Development Expert Biologics

This seminar is the basic module of our Development Expert Biologics qualification programme.

The course concept:

  • You attend our basic course "Biopharmaceuticals"
  • Afterwards you will take part in 3 further seminar modules (= 3 seminar days), which you can put together individually from the course curriculum
  • You will receive structured further training and comprehensive knowledge on topics relating to the development and production of biologics
  • You can specialise according to your main area of activity through the targeted selection of seminars

For more information, please visit our Website


Benefits of a FORUM Institut training course

FORUM Institut’s all-in-one training platform uses the latest teaching methods.
All our online training courses take place in the Learning Space, our holistic learning environment with many features that promote effective and sustainable learning.

  • Live and interactive learning on our Learning Space training platform
  • A platform with many features: events rooms, chat, course agendas and documents, surveys, workshop rooms and much more
  • Easy surveys with Slido
  • ‘Deluxe’ chat: group chats, one-to-one chats, one-to-one video chats
  • A central repository for documents and media
  • Other services and apps such as Padlet and Mentimeter available directly on the platform
  • The perfect marriage of teaching methods and technology
  • High level of interactivity with plenty of opportunity for questions
  • Continuous support throughout the event to ensure the most effective learning
  • Free technical pre-meeting to start off your training on the right foot


Free pre-meeting and technology check

You can attend one of our pre-meetings and explore our Learning Space free of charge. Registration is not required. You can find available dates for a pre-meeting in your customer portal. Click the green ‘Participate’ button in the pre-meeting in the customer portal and you will be redirected to the Learning Space.

The pre-meeting gives you the opportunity to explore our Learning Space and to familiarise yourself with the technology to start off your online training on the right foot. This is a non-binding offer for all our customers and not a prerequisite for participation. If a pre-meeting date does not suit you but you would still like a technology check, please contact us.

This is what distinguishes this event

Modules

Hours of learning content

In-house Offers - On-site and Online

We also conduct this seminar exclusively for your company - individually tailored to your requirements, flexible scheduling and available as either on-site or online format. Contact us and we will prepare a customized offer for you.

Request a quote

Our Recommendations

Thema
Dates
Format

Further Information

List of abbreviations pharma & healthcare

Many abbreviations are used in pharma & healthcare. Download the list of the most important ones.

Details

In-house seminars

Our programmes are also available for in-house training. Just contact us!

Details

Our rating in 2025

More than 3,700 customers have rated our training courses. Thank you for awarding us 4.4 stars out of 5.

Details

Your Contact Person

We are happy to advise you personally and individually.

Our further education offerings are comprehensive. We are happy to personally match your requirements with our offerings. Let our further education experts advise you and contact us today.

Dr. Birgit Wessels
Conference Manager
+49 6221 500-652
b.wessels@forum-institut.de